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The mechanistic links between genetic variation
and autoantibody production in autoimmune disease
remain obscure. Autoimmune lymphoproliferative
syndrome (ALPS) is caused by inactivatingmutations
in FAS or FASL, with autoantibodies thought to arise
through failure of FAS-mediated removal of self-reac-
tive germinal center (GC) B cells. Here we show that
FAS is in fact not required for this process. Instead,
FAS inactivation led to accumulation of a population
of unconventional GCB cells that underwent somatic
hypermutation, survived despite losing antigen reac-
tivity, and differentiated into a large population of
plasma cells that included autoantibody-secreting
clones. IgE+ plasma cell numbers, in particular,
increased after FAS inactivation and a major cohort
of ALPS-affected patients were found to have hy-
per-IgE. We propose that these previously unidenti-
fied cells, designated ‘‘rogue GCB cells,’’ are amajor
driver of autoantibody production and provide a
mechanistic explanation for the linked production of
IgE and autoantibodies in autoimmune disease.
INTRODUCTION
Production of pathogenic antibodies by B lymphocytes con-
tributes significantly to inflammatory disease. Autoantibodies,
typically of the immunoglobulin G (IgG) class, are involved in
many human autoimmune diseases including systemic lupus ery-
thematosus (SLE), bullous pemphigoid (BP), and autoimmune
lymphoproliferative syndrome (ALPS). Additionally, airborne or in-
gested proteins can trigger the production of IgE,with resulting in-
ductionofallergicdiseasessuchasasthmaand foodallergies.The
processes that regulate autoantibody and allergic IgE production890 Immunity 42, 890–902, May 19, 2015 ª2015 Elsevier Inc.are often considered separately because of the distinct nature of
the antigens targeted (self versus foreign). Nevertheless, the pres-
ence of IgE aswell as IgG autoantibodies in autoimmunediseases
hasbeen recognized since the 1970s (Permin andWiik, 1978;Pro-
vost and Tomasi, 1974) and strong evidence exists that IgE auto-
antibodiescontribute todiseasepathogenesis inBP (Messingham
et al., 2014) aswell as human andmurine SLE (Dema et al., 2014a,
2014b). However, the mechanisms underlying the production of
IgE together with IgG autoantibodies remain unknown.
A key component of adaptive humoral immunity is the
germinal center (GC) reaction. GCs are transient microanatom-
ical structures in which B cells activated by foreign antigen un-
dergo iterative cycles of proliferation and somatic hypermutation
(SHM) of their Ig variable region genes to yield the high-affinity
antibodies required for long-term immunity (Victora and Nus-
senzweig, 2012). Because of the random nature of SHM, the
development of self-reactive B cells within the GC is inevitable
(Nossal, 1988). We showed recently that self-reactive B cells
are rapidly removed from theGCand thus prevented fromunder-
going differentiation into autoantibody-producing plasma cells
(PCs) (Chan et al., 2012). However, this process is compromised
under some circumstances as indicated by the fact that GCs are
amajor source of pathogenic IgG autoantibodies (Brink, 2014). In
particular, mutations affecting the expression and/or function of
molecules involved in the removal of self-reactive GC B cells are
likely to make significant contributions to autoimmune diseases
such as SLE, BP, and ALPS.
The pro-apoptotic TNF receptor superfamily member FAS
is highly expressed on GC B cells (Liu et al., 1995; Smith et al.,
1995). Mutations in the genes encoding FAS or its ligand
(FASL) result in ALPS in humans (Fisher et al., 1995; Rieux-Lau-
cat et al., 1995;Wu et al., 1996) andmodel ALPS and SLE inmice
(Andrews et al., 1978; Takahashi et al., 1994; Watanabe-Fuku-
naga et al., 1992). Significantly, the selective removal of FAS
from activated B cells results in ALPS-like disease and autoanti-
body production (Hao et al., 2008). These findings have led to a
widely accepted view that the autoimmune predisposition of in-
dividuals with FAS/FASLmutations derives at least in part from a
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Figure 1. FAS-Mediated Apoptosis Is Not
Required to Remove Conventional Self-
Reactive GC B Cells
SWHEL or SWHEL.Fas
lpr/lpr B cells were transferred
into wild-type or mHEL4X Tg recipient mice, chal-
lenged with HEL3X-SRBCs, and analyzed on day
21. Data are representative of three independent
experiments.
(A) Left: Flow cytometric analysis of donor-derived
splenicGCBcells (CD45.1+CD45.2B220+CD38lo).
Profiles are concatenated from fourmice per group.
Right: Summary data from one experiment indi-
cating the proportion of HEL4X-binding cells among
IgG1+ GC B cells using the windows shown on the
flow cytometry panels.
(B) Single-cell SHM analysis of donor-derived
splenic GC B cells. Mutations that increase or
decrease the affinity of Y53D for HEL4X are S31R/
Y58F and L4F/N94K, respectively (see Figure S1).
n = number of clones analyzed. Data were ob-
tained from three pooled wild-type or mHEL4X Tg
recipient mice. Data from wild-type donor SWHEL
B cells have been previously published (Chan
et al., 2012).
(C) Endpoint titers of HEL4X-binding IgG1 deter-
mined by serum ELISA.failure to eliminate self-reactive GC B cells (Aı¨t-Azzouzene et al.,
2010; Hao et al., 2008). Nevertheless, direct evidence that FAS
carries out this function in the GC has remained elusive.
Here we utilize a high-resolution in vivomurinemodel to unam-
biguously identify the role of FAS in controlling GC B cells. FAS
was found to be dispensable for the removal of conventional
self-reactive GC B cells. FAS expression by responding B cells
was instead found to be essential for preventing the emergence
of a population of unconventional ‘‘rogue’’ GC (GCr) B cells that
persist and undergo SHM and PC differentiation independent of
normal antigen-dependent regulation. Surprisingly, PCs derived
from GCr (PCr) B cells included a large fraction of IgE-producing
cells, leading us to identify a large cohort of non-atopic human
ALPS patients with hyper-IgE. A proportion of PCr B cells also
developed autoreactivity and produced high titers of serum
autoantibodies. The identification of GCr B cells explains
how B-cell-expressed FAS safeguards against autoantibody re-
sponses. It also provides a mechanism for the previously unex-
plained link between IgG and IgE autoantibody production in
antibody-mediated autoimmune diseases.
RESULTS
FAS Expression Is Not Required for the Deletion of
Self-Reactive GC B Cells
To test whether FAS is required for the elimination of self-reactive
GCBcells,wecompared the in vivo responsesof antigen-specific
Bcells that differed only in their ability to express FAS.B cells from
wild-type or FAS-deficient (Faslpr/lpr) SWHEL mice (expressing theImmunity 42, 890–9hen egg lysozyme [HEL] specificity of the
HyHEL10 mAb) (Phan et al., 2003) were
transferred into CD45 congenic recipient
mice (CD45.1+ cells into CD45.2+ mice)andchallengedwithantigen in the formof recombinantHEL3Xpro-
tein (HELR21Q,R73E,D101R) coupled to sheep redblood cells (HEL3X-
SRBCs) (Paus et al., 2006). SWHEL B cells bind HEL
3X with an af-
finity (Ka) of 107 M1 but cannot recognize the closely related
HEL4X protein (HEL3X,K97R) (Chan et al., 2012). In wild-type
recipient mice, SWHEL GC B cells acquire cross-reactivity with
HEL4X as they undergo affinity maturation to HEL3X (Figure 1A).
In membrane HEL4X transgenic (mHEL4X Tg) recipients, however,
self-tolerance prevents such cells from accumulating (Figure 1A;
Chan et al., 2012). When SWHEL.Fas
lpr/lpr donor B cells were
used, self-reactiveHEL4X-bindingGCBcells still failed to develop
in mHEL4X Tg recipients (Figure 1A), and clones carrying the
HEL4X-reactive Y53D Ig heavy chain substitution were strongly
counter-selected or edited with complementary, deleterious so-
matic mutations (Figures 1B and S1; Chan et al., 2012). Accord-
ingly, anti-HEL4X serum antibody was absent from mHEL4X Tg
recipients on day 21 of the response regardless of whether or
not the donor SWHEL B cells expressed FAS (Figure 1C). Thus,
contrary to previous assumptions (Aı¨t-Azzouzene et al., 2010;
Hao et al., 2008), the expression of FAS by self-reactive B cells
generated within the GC is not required for their elimination.
FAS-Deficient Mice and Humans Produce Large
Amounts of IgE Antibodies
Although self-reactive GC B cells were removed normally, the
response of SWHEL.Fas
lpr/lpr B cells to HEL3X-SRBCs did exhibit
aberrant features. Notably, splenic basophils from recipient mice
(CD45.2+B220c-KitCD49b+) acquired high HEL-binding activ-
ity in recipients of SWHEL.Fas
lpr/lpr B cells but not in recipients of02, May 19, 2015 ª2015 Elsevier Inc. 891
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Figure 2. FASL-FAS Suppress IgE Antibody
Production in Mice and Humans
(A and B) Flow cytometric analysis of endogenous
splenic basophils (CD45.2+B220c-KitCD49b+)
in wild-type recipients of SWHEL or SWHEL.Fas
lpr/lpr
B cells. Note that the anti-FcεRI mAb is blocked by
receptor-bound IgE. Data are representative of
two independent experiments.
(C) SWHEL, SWHEL.Fas
lpr/lpr, or SWHEL.Fasl
Dm/Dm B
cells were transferred into wild-type recipient mice
and challenged with HEL3X-SRBCs, and sera was
taken at days 14 and 21 and analyzed by ELISA.
HELWT-binding IgE (left) was determined by
endpoint titer and total IgE was also measured
(right). Data are representative of two independent
experiments.
(D) Total serum IgE in 16- to 18-week-old wild-type
C57BL/6 mice compared to those lacking func-
tional FAS (Faslpr/lpr, FasD/D) or FASL (Faslgld/gld,
FaslDm/Dm).
(E) Total serum IgE in ALPS patients and healthy
relatives. Data points < 90 U/ml not shown.
For all figures, significant differences are indicated
by asterisk(s). A full explanation of statistical ana-
lyses is available in the Experimental Procedures.wild-type SWHEL B cells (Figure 2A). This occurred regardless of
the recipients’ expression of mHEL4X (data not shown). Flow cy-
tometric analysis via amAb that is blocked frombinding the high-
affinity IgE receptor (FcεRI) by receptor-bound IgE revealed that
the FcεRI on these basophils were almost completely saturated
with anti-HEL IgE (Figure 2B), suggesting that SWHEL.Fas
lpr/lpr B
cells were generating large amounts of IgE antibody when chal-
lenged with HEL3X-SRBCs.
To test this directly, serum antibody responses in wild-type
recipient mice were analyzed on day 21 after transfer and
challenge of SWHEL or SWHEL.Fas
lpr/lpr B cells. An additional
group received SWHEL B cells lacking the membrane form of
FASL (SWHEL.Fasl
Dm/Dm B cells) (O’ Reilly et al., 2009). SWHEL
and SWHEL.Fasl
Dm/Dm B cells challenged with HEL3X-SRBCs in
wild-type recipient mice failed to mount serum IgE responses
(Figure 2C). In contrast, SWHEL.Fas
lpr/lpr B cells initiated a strong
response, with anti-HEL serum IgE reaching 5–10 mg/ml by day
21 (Figure 2C), verifying that B cells lacking FAS (but not mem-
brane FASL) produce anomalously high IgE antibody responses.
A link between FAS deficiency and IgE production has been
suggested from observations in Faslpr/lpr BALB/c mice (Takaha-892 Immunity 42, 890–902, May 19, 2015 ª2015 Elsevier Inc.shi et al., 2013). We confirmed that a
similar connection exists on the C57BL/
6 genetic background, as shown by the
fact that mice lacking active FAS due
to either a natural (Faslpr/lpr) or induced
(FasD/D) mutation possess serum IgE
concentrations 50–100 times higher than
those in wild-type controls (Figure 2D).
C57BL/6 mice in which FASL binding to
FAS was disrupted by a natural mutation
(Faslgld/gld) or altered such that the mem-
brane form of the ligand (essential for
FAS-mediated apoptosis) can no longerbe expressed (FaslDm/Dm) possessed a similar hyper-IgE
phenotype (Figure 2D). Overall, these results indicated that the
interaction of membrane-bound FASL with FAS expressed on
responding B cells suppresses IgE antibody production in mice.
Abnormally high serum IgE is not a recognizedclinical feature of
ALPS. However, because FAS-FASL function is highly conserved
betweenhumansandmice (Fisher et al., 1995;Rieux-Laucatet al.,
1995;Takahashi et al., 1994;Watanabe-Fukunagaetal., 1992;Wu
et al., 1996), we hypothesized that a subset of ALPS-affected pa-
tients would exhibit a hyper-IgE phenotype. Strikingly, retrospec-
tive analysis of clinical data from 150 patients and 63 unaffected
relatives in theNational InstituteofAllergy and InfectiousDiseases
ALPS-FAS study (Price et al., 2014) revealed that 25% of ALPS-
affected patients possessed serum IgE concentrations 10–8,000
times higher than the upper limit of the normal range (90 U/ml)
and only 3% of healthy relatives fell into this category (Figure 2E).
Interestingly, there was no increase in the incidence of allergic
diseases among ALPS-affected patients with hyper-IgE (data
not shown). Taken together, these data indicate that FAS plays
a critical and conserved role in limiting the production of IgE in
both humans and mice.
Figure 3. FAS-Deficient B Cells Generate
Large Numbers of IgG1+ and IgE+ PCs
SWHEL or SWHEL.Fas
lpr/lpr B cells were transferred
into wild-type recipient mice, challenged with
HEL3X-SRBCs, and analyzed on day 21.
(A) Flow cytometric analysis of donor-derived
splenic GC B cells plus PCs (CD45.1+CD45.2
CD38lo; see Figure S2A) using staining for total
IgG1 and intracellular (i.c.) IgE after cell fixation
and permeabilization. IgG1+ GC = IgG1loIgE;
IgG1+ PC = IgG1hiIgE; IgE+ PC = IgG1IgEhi.
(B) Histogram overlay of forward light scatter (FSC)
of indicated populations of donor-derived cells
from (A).
(C and D) Flow cytometric analysis of donor-
derived GC B cells plus PCs as for (A) showing
surface B220 expression.
Plots in (A)–(D) comprise concatenated data from
five mice and are representative of three inde-
pendent experiments.
(E) Single-cell qPCR analysis of donor-derived
subsets (see Figure S2B for gating) from splenic
SWHEL.Fas
lpr/lpr response. Relative mRNA expres-
sion is indicated from high (red) to low (blue).
(F) Immunofluorescence histology of SWHEL
and SWHEL.Fas
lpr/lpr responses in recipient spleens.
Colors representing the various stainsare indicated.FAS-Deficient B Cells Produce Large Numbers of IgG+
and IgE+ PCs
To characterize the FAS-deficient cells responsible for IgE
production, SWHEL and SWHEL.Fas
lpr/lpr B cells were challenged
with HEL3X-SRBCs in wild-type recipient mice, identified by flow
cytometry, (Figure S2A) and analyzed for IgE expression. IgG1+
cellswere also examinedbecause these typically form theprecur-
sors for IgE-switched cells and IgG1 is the major Ig subclass pro-
duced after challenge of SWHEL B cells with HEL
3X-SRBCs (Chan
et al., 2009; Erazo et al., 2007; Yang et al., 2012). Because previ-
ous studies had indicated that IgE-switchedB cells exist primarily
as plasma cells (PCs) (Erazo et al., 2007; Yang et al., 2012), donor-
derived (CD45.1+CD45.2) B cells were stained for IgG1 and IgE
after fixation andpermeabilization to access intracellular antibody
stores and thus resolvebrightly stainingPCs from theirmoredimlyImmunity 42, 890–staining GC B cell counterparts. To avoid
detecting surface CD23-bound IgE, sam-
ples were blocked with unconjugated
anti-IgE before cell permeablization and
intracellular IgE stores selectively stained
with conjugated anti-IgE antibody (Yang
et al., 2012). On day 21, wild-type SWHEL
B cell responses were characterized by a
large IgG1+GCpopulation, small numbers
of IgG1hiPCs, andavirtual absenceof IgE+
cells (Figure 3A). In contrast, the response
of SWHEL.Fas
lpr/lpr B cells included a 50- to
100-fold expansion of IgG1hi PCs and the
emergence of a clearly resolvable popula-
tion of IgEhi PCs (Figure 3A). As expected,
IgE+ GCB cells were rare presumably due
to their transient nature (Yang et al., 2012).IgG1hi and IgEhi cells were verified as PCs by their larger size (for-
ward light scatter) relative to IgG1+GCBcells (Figure 3B) and their
B220lo phenotype (Figures 3C and 3D). Single-cell analysis (Fig-
ure S2B) of cells from the various SWHEL.Fas
lpr/lpr B-cell-derived
populations revealed gene expression profiles corresponding to
those expected for GC B cells and PCs (Figure 3E). Finally, IgE+
cells were also located exclusively within the extrafollicular re-
gions of the spleen (Figure 3F), consistent with their identity as
antibody-secreting PCs.
IgE+ PCs Arise Late in the Response and Derive fromGC
B Cell Precursors
We next performed a kinetic analysis on the responses of SWHEL
B cells lacking functional FAS due to either the Faslpr mutation
(SWHEL.Fas
lpr/lpr) or targeted ablation of the FAS cytoplasmic902, May 19, 2015 ª2015 Elsevier Inc. 893
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Figure 4. FAS-Deficient IgG1+ and IgE+ PCs Derive from GC B Cell Precursors
(A) Time course of donor-derived splenic responses of SWHEL, SWHEL.Fas
lpr/lpr, and SWHEL.Fas
D/D B cells. Data pooled from two independent experiments.
(B) Volcano plot of qPCR data from Figure 3E (SWHEL.Fas
lpr/lpr B cell response to HEL3X-SRBCs) showing fold-change and p values for individual genes between
IgG1+ GC B cells and IgG1+ or IgE+ PCs.
(C) Overlay of CD40 staining on cells derived from day 14 splenic response of SWHEL.Fas
lpr/lpr B cells to HEL3X-SRBCs.
(D) Frequency of splenic donor-derived subsets from SWHEL.Fas
lpr/lpr B cells challenged with HEL3X-SRBC on day 21 after 5 days treated with blocking anti-
CD40L antibody or isotype control.
(E) Mutation rates in the Ig heavy chain variable region gene in donor-derived splenic subsets (see Figure 3B for gating) from SWHEL or SWHEL.Fas
lpr/lpr B cells
challenged with HEL3X-SRBCs. n = number of clones analyzed. Error bars indicate the SEM.domain (SWHEL.Fas
D/D). The early (day 6) response mounted by
FAS-deficient and wild-type SWHEL B cells included a burst of
IgG1+ PCs but no detectable IgE+ PCs (Figure 4A). IgE+ PCs
did not emerge until between days 9 and 12 of the response
and only when responding B cells lacked functional FAS. The
appearance of IgE+ PCs corresponded with a second wave of
IgG1+ PCs from FAS-deficient SWHEL B cells and a 5-fold894 Immunity 42, 890–902, May 19, 2015 ª2015 Elsevier Inc.expansion in IgG1+ and total GC B cells (Figures 4A and S3A).
This late emergence of IgE+ PCs in parallel with GC expansion
suggested that IgE+ PCs are derived from GC B cell precursors
rather than from persistence of early GC-independent plasma-
blasts (Chan et al., 2009; William et al., 2002).
To test this proposition, we first examined the effect of ablating
the GC B cell response with anti-CD40L mAb (Han et al., 1995a).
Because the PCs produced by SWHEL.Fas
lpr/lpr B cells do not ex-
press CD40 (Tnfrsf5) (Figures 3E, 4B, and 4C), they should be
resistant to CD40L blockade if they represent a persisting auton-
omous population derived from the early plasmablast response.
On the other hand, if they are continually replenished from GC
precursors, they will be depleted in parallel with GC B cells.
Examination of the day 21 SWHEL.Fas
lpr/lpr B cell response to
HEL3X-SRBCs after 5 days of treatment with anti-CD40L showed
that the latter scenario applied, with the numbers of GCB cells as
well as IgG1+ and IgE+ PCs in each case depleted by 10-fold
(Figure 4D). Further confirmation that these PCs are replenished
from GC precursors was provided by single-cell sorting (Fig-
ure S3B) and SHM analysis. As predicted, both IgG1+ and IgE+
PCs were somatically mutated and showed increased SHM
frequency over the course of the SWHEL.Fas
lpr/lpr B cell response
(Figure 4E). Because the PCs produced by SWHEL.Fas
lpr/lpr B
cells do not express AID (Aicda) (Figures 3E and 4B), they could
not undergo SHM autonomously but must be replenished from
AID-expressing, somatically mutating GC B cell precursors.
FAS-Deficient GCr B Cells Escape Normal Selection and
Produce IgG+ and IgE+ PCs
The production of PCs from GC B cell precursors is normally
tightly regulatedsuch that only those cloneswith thehighest affin-
ity for antigen are selected to undergo PC differentiation (Phan
et al., 2006). This is evident in day 21 responses of SWHEL B cells
to HEL3X-SRBCs where, similar to IgG1+ GC B cells, IgG1hi
PCs bind large amounts of HEL3X when stained with limiting con-
centrations of antigen (Figure 5A). They also invariably carry the
high-affinity Ig heavy chain substitutionY53D, oftenwith the addi-
tional affinity-enhancing substitutions S31R and/or Y58F (Fig-
ure 5C; Chan et al., 2012; Phan et al., 2006). In contrast, very
few of the IgG1hi and IgEhi PCs produced during the
SWHEL.Fas
lpr/lpr B cell response bound HEL3X with high affinity
(Figure 5B) or carried mutations normally associated with affinity
maturation to HEL3X (Y53D, S31R, Y58F) (Figure 5D). Paradoxi-
cally, affinitymaturation of SWHEL.Fas
lpr/lpr GCBcells progressed
relatively normally,withmost developing high affinity for HEL3X as
indicated by flow cytometry (Figure 5B) and SHM analysis (Fig-
ure 5D). Absent FAS expression on responding B cells therefore
disrupts the normal regulation of PC differentiation, favoring the
production of PCs from ‘‘rogue,’’ non-affinity regulated precur-
sors that must exist at relatively low frequencies within the GC.
To investigate this further, we first bred SWHEL.Fas
lpr/lpr mice
onto aRag1D/D background to eliminate the possibility that these
rare GCr B cells might express an alternative BCR. B cells from
SWHEL.Fas
lpr/lpr.Rag1D/D mice responded identically to those
from SWHEL.Fas
lpr/lpr mice, generating expanded numbers of
somatically mutated IgG1+ and IgE+ PCs that showed little evi-
dence of affinity maturation to HEL3X (Figures S4C and S4D).
SHM analysis of donor-derived spleen cells from mice given
SWHEL.Fas
lpr/lpr.Rag1D/D B cells and HEL3X-SRBCs revealed
that IgG1+ and IgE+ PC populations were both clonally restricted
and clonally related within individual recipient mice (Figures 5E
and S5). IgG1+ GC B cells clonally related to these PCs were
rare and typically represented only 1%–3% of GC B cells (Fig-
ures 5E and S5) but could be enriched by isolation of IgG1+
GCB cells with low affinity for HEL3X. By this approach, sufficient
numbers of related GC clones were obtained to facilitate adetailed analysis of the clonal evolution of a family of GCr B cells
and their PC derivatives (PCr). This analysis revealed that the
generation of PCr from GCr B cells is an ongoing process in
which multiple PC differentiation and IgE switching events occur
(Figure 5F). Moreover, as predicted by their abnormal SHM pat-
terns and low HEL3X-binding activity, mAbs carrying the variable
regions expressed by these clones bound HEL3X antigen with
low and often biologically irrelevant (Ka < 10
5 M1) affinities
(Figure S5A). Unlike the SHM patterns that arise during affinity
maturation, the amino acid substitutions observed among rogue
FAS-deficient clones were unique to individual mice (Figures 5E
and S5). Nevertheless, PCr from individual mice were never
observed to be from just a single clonal family (e.g., Figure S5B),
indicating that these cells derive from multiple ancestral clones
and possibly distinct GCs.
GCr B Cells Accumulate and Generate Late-Response,
Autoantibody-Secreting PCs
Because GCr B cells exhibit ongoing SHM and PC differentiation
and are not subject to conventional antigen regulation, we postu-
lated that the emergence and accumulation of such cells might
be responsible for the production of autoantibodies that ensues
when B cells lack functional FAS. To test this possibility, we first
examined the extent to which GCr B cells accumulate over
the course of FAS-deficient B cell responses. As previously
observed (Figures 5C and 5D), early GC B cell affinity maturation
occurs regardless of B cell FAS expression, with >90% of both
SWHEL and SWHEL.Fas
lpr/lpr GC B cells exhibiting high affinity
for HEL3X as well as the Y53D substitution on day 14 of the
response (Figures 6A and 6B). As expected, high-affinity wild-
type SWHEL GC B cell clones remained dominant until at least
day 35 of the response. In contrast, low-affinity and Y53D
clones progressively accumulated in GCs derived from
SWHEL.Fas
lpr/lpr GC B cells, resulting in a ‘‘heretical’’ reversal of
affinity maturation between days 14 and 35 of the response
(Figures 6A and 6B). Correspondingly, sequence analysis of
donor-derived cells from single recipient mice at late time points
revealed increased clonal restriction within the GC such that
clear groups of related (Y53D) GCr clones with corresponding
populations of expanded PCr often reached 10%–15% of the
GC by days 35–42 (Figure S6) as opposed to 1%–3% on day
21 (Figures 5 and S5). Taken together, these data indicate that
GCr B cells become increasingly prevalent over the course of
responses mounted by SWHEL.Fas
lpr/lpr B cells.
We next determined whether the proclivity of GCr B cells to
differentiate into PCs evident on day 21 was maintained at later
stages of the response. Analyses performed on day 35 showed
that, although wild-type SWHEL PCs were completely absent
by this time, a large fraction of both the total and IgG1+ splenic
response of SWHEL.Fas
lpr/lpr donor B cells was still comprised
of PCs (Figures 6C and 6D). These cells showed the character-
istic clonal restriction (Figure S6) and lack of antigen binding
(data not shown) of PCr.We therefore concluded that GCr B cells
not only persist and form an increasingly large fraction of the
GC response of FAS-deficient B cells but that they continue to
produce antibody-secreting PCr long after the conventional PC
production has shut down.
Finally, we tested whether the ongoing response by FAS-defi-
cient GCr B cells results in the eventual production ofImmunity 42, 890–902, May 19, 2015 ª2015 Elsevier Inc. 895
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Figure 6. GCr B Cells Accumulate, Display
Abnormal Antigen Selection, and Continue
to Generate PCr
SWHEL or SWHEL.Fas
lpr/lpr B cells were challenged
with HEL3X-SRBCs in wild-type recipients as for
Figure 5. Splenocytes were harvested at the
indicated time points.
(A) Left: Cell surface staining with limiting
(50 ng/ml) HEL3X antigen to distinguish high- and
low-affinity GC B cells. Right: Summary data from
two experiments (combined) indicating the pro-
portion of non-HEL3X-binding cells among IgG1+
GC B cells on day 35 using the windows shown on
the flow cytometry panels.
(B) SHM analysis of IgG1+ GC B cells for clones
carrying the high-affinity anti-HEL3X Y53D substi-
tution. n = number of clones analyzed.
Late responses of SWHEL.Fas
lpr/lpr B cells show
anomalous accumulation of low-affinity (A) and
Y53D (B) GC B cells.
(C and D) Identification of B220lo PCs in CD38lo
donor-derived cells on day 35 response of
SWHEL.Fas
lpr/lpr but not SWHEL B cells as revealed
by high forward light scatter (FSC) (C) and
high total IgG1 staining after fixing and per-
meablization (D).autoantibodies. To do this, we returned to the HEL4X Tg transfer
system utilized at the beginning of this study and examined
whether self-tolerance, intact during the early response of
SWHEL.Fas
lpr/lpr B cells in HEL4X Tg recipient mice (Figure 1),
might break down at later stages when GCr and PCr become
prominent. Measurement of serum anti-HEL4X autoantibody
concentrations revealed that they remained undetectable in
HEL4X Tg recipient mice over the course of the response of
wild-type SWHEL B cells to HEL
3X-SRBCs (Figure 7A). In
contrast, anti-HEL4X autoantibodies accumulated in HEL4X Tg
recipients of SWHEL.Fas
lpr/lpr B cells such that, by day 35, the
majority of mice exhibited high titers of serum anti-HEL4X IgG1Figure 5. FAS-Deficient IgG1+ and IgE+ PCs Develop from GCr B Cells that Escape Normal An
(A–D) SWHEL or SWHEL.Fas
lpr/lpr B cells were challenged with HEL3X-SRBCs as for Figure 3.
(A andB) Flow cytometric analysis as for Figures 3C and 3D except counterstained for binding of limiting (50 ng
affinity antibodies. Plots comprise concatenated data from five mice and are representative of three indepe
(C and D) Ig heavy chain variable region replacement mutations in responding cell subsets. HEL3X affinity
highlighted. n, number of clones analyzed; SHM, mean number of mutations per clone.
(E) Ig heavy chain variable region replacement mutations in clonally related cells obtained from a single w
response of SWHEL.Fas
lpr/lpr.Rag1D/D B cells to HEL3X-SRBCs. Percentages indicate the frequency of the re
ulations. IgG1+ GC clones include 2/58 from unfractionated cells and 4/40 from the 20% of cells with the lo
(F) A common ancestral GC clone carrying the S52N, S54N, T84A, and Y102F substitutions diversified into a
clonal expansion, and PC differentiation steps (SHM was assumed to be limited to GC B cells). Four indepe
circles).
Immunity 42, 890–(Figure 7A) and IgG2b (data not shown;
anti-HEL4X IgE was not detectable). Veri-
fication that PCr were responsible for
this production of anti-HEL4X autoanti-
bodies was obtained by the identification
of donor-derived, HEL4X-binding, IgG1+
and IgG1 PCs (Figures 7B and 7C). Sin-
gle-cell sorting and analysis of the heavychain variable regions of these clones revealed the clonal restric-
tion patterns typical of PCr but including substitutions (Y53D,
Y53N, Y58F) known to increase the affinity of HyHEL10 for
HEL4X (Figure S7). Accordingly, the core mutations present in
each of three independent clonal PCr families identified in sepa-
rate HEL4X Tg recipients were verified to possess affinities (Ka)
for HEL4X ranging from 107 to more than 5 3 108 M1 (Fig-
ure 7D). Overall, these results demonstrate that B cell FAS is
not required for the removal of conventional self-reactive GC B
cells but is absolutely necessary to prevent the development
and persistence of GCr B cells that escape normal antigen regu-
lation and initiate IgE and autoantibody production.tigen Regulation
/ml) HEL3X antigen to identify cells expressing high-
ndent experiments.
-increasing mutations Y53D, S31R, and Y58F are
ild-type recipient mouse (71.06) on day 21 of the
lated clones within the respective responder pop-
west HEL3X-binding activity.
ll 39 clones identified in (E) via the indicated SHM,
ndent IgE switching events were identified (yellow
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Figure 7. GCr B Cells Produce Autoanti-
body-Secreting PCr Late in the Response
of SWHEL.Fas
lpr/lpr B Cells to HEL3X-SRBCs
SWHEL or SWHEL.Fas
lpr/lpr B cells were challenged
with HEL3X-SRBCs in wild-type or mHEL4X Tg re-
cipients as for Figure 1. Splenocytes and blood
were harvested at the indicated time points.
(A) HEL4X-binding IgG1 serum antibodies were
measured by ELISA and reveal the absence (day
14), the initial emergence (day 21), and the accu-
mulation (day 35) of autoantibodies in mHEL4X Tg
recipients of SWHEL.Fas
lpr/lpr but not SWHEL B
cells.
(B and C) Detection of self-reactive PCs in mHEL4X
Tg recipients of SWHEL.Fas
lpr/lpr B cells on day 35
of the response to HEL3X-SRBCs.
(B) Donor-derived CD38lo cells analyzed for
HEL4X-binding and total IgG1 after fixing and
permeablization showing IgG1+ and IgG1 self-
reactive PCs.
(C) Independent mHEL4X Tg recipients showing
self-reactive PC populations subjected to single-
cell sorting and SHM analyses. Core mutations in
each family of clones are shown and substitutions
known to increase affinity for HEL4X underlined.
(D) Binding affinities of recombinant HyHEL10
IgG1 carrying the core mutations from the clone
families identified in (C) for foreign (HEL3X) and self
(HEL4X) antigens. See Figure S7 for further details.DISCUSSION
Two decades have passed since the first studies demonstrated
that FAS expressed on activated human and mouse B cells can
mediate their death (Garrone et al., 1995; Rathmell et al., 1995).
Nevertheless, the precise role of FAS in regulating in vivo B cell
responses and particularly the GC reaction has been controver-
sial. It has been concluded that FAS has no significant role to
play in the GC (Smith et al., 1995) and is not required to remove
self-reactive GC B cells (Alabyev et al., 2008; Han et al., 1995b).898 Immunity 42, 890–902, May 19, 2015 ª2015 Elsevier Inc.On the other hand, FAS-deficient mice
have been found to display aberrant GC
Bcell selection (Hochet al., 2000; Takaha-
shi et al., 2001), to develop self-reactive B
cells in certain models (Aı¨t Azzouzene
et al., 2010), and to produce autoanti-
bodieswhen FAS inactivation is restricted
to B cells (Hao et al., 2008). Amajor aim of
the current study was to gain new per-
spectives on this unresolved issue by us-
ing a high-resolution in vivo mouse model
to provide a detailed and comprehensive
analysis of how the responses of anti-
gen-specific B cells are affected when
they specifically lack FAS. The results
not only help reconcile many of these pre-
vious findingsbut alsopoint to a newclass
of activated lymphocyte, the rogue GC
(GCr) B cell, as a potent source of IgE
and autoantibody production and the rai-
son d’eˆtre for FAS expression in the GC.The initial result of this study was that FAS was not required to
remove self-reactive GC B cells. This is in agreement with the in-
terpretations of some (Alabyev et al., 2008; Han et al., 1995b) but
not other (Aı¨t Azzouzene et al., 2010; Hao et al., 2008) earlier in-
vestigations. Although it could be argued that different results
might be obtained in different systems, the question of whether
FAS is required to maintain GC B cell self-tolerance can also be
answered differently depending on the readout of tolerance that
is employed. In our study, FAS was clearly not required for the
removal of conventional GC B cells that acquire self-reactivity
against mHEL4X. However, looking later in the response, it was
equally clear that serum anti-HEL4X autoantibodies accumulated
to high titers specifically in recipients of FAS-deficient B cells.
These results could be reconciled by the fact that a previously
unknown population of cells, GCr B cells, emerged over the
course of the response of FAS-deficient B cells. Because these
cells do not follow the same rules of selection as their conven-
tional counterparts, SHM ultimately leads to the unchecked pro-
duction of autoantibody-secreting PCr and the breakdown of
self-tolerance. Thus, although one mechanism of self-tolerance
remains intact when GC B cells lack FAS, another fails, which
might well explain the previous confusion over the role of FAS
in maintaining GC B cell self-tolerance.
A major question to arise from this study is what drives the
survival and accumulation of GCr B cells? These cells are not
dependent on recognition of the immunizing antigen and so differ
fundamentally from conventional GC B cells. Could they instead
be selected on the basis of interactions with certain self-anti-
gens? From our analysis of the specificities encoded by GCr
and PCr B cells, it seems unlikely that specific self-antigens drive
the accumulation of these cells. Thus, although there are strong
clonal relationshipswithin individual recipients of SWHEL.Fas
lpr/lpr
B cells, recurring amino acid substitutions (such as those seen in
affinity maturation to HEL3X) are not observed between recipi-
ents. An alternative possibility is that GCr B cells exist because
they have acquired mutated antigen receptors that undergo
some form of structural change (e.g., auto-aggregation) that re-
sults in their ‘‘selection’’ independent of antigen recognition. In
this case, the acquisition of self-reactivity by rogue cells might
be incidental but (at a population level) highly likely based on their
ongoing SHM. Finally, the restricted clonality of GCr B cellsmight
be explained by an ancestral clone acquiring amutation in a non-
Ig gene (e.g., by off-target SHM) that allows the clone and its
daughter cells to be perpetuated without retaining antigen spec-
ificity. Here again, self-reactivity might arise as a consequence of
ongoing SHM being uncoupled from the need to maintain recog-
nition of the original immunizing antigen. This raises the question
of how T cells, presumably GC-localized Tfh cells, could be
required to maintain GCr B cells as is indicated by our CD40L-
depletion data? One possibility is that they are able to maintain
the peptide-MHC complexes as they continue dividing without
requiring ongoing antigen contact (Thaunat et al., 2012). Alterna-
tively, they might be able to persist on the basis of ‘‘bystander’’
help that they can access without undergoing cognate interac-
tions with Tfh cells.
Whatever the specificmechanism is that drives the production
of GCr B cells, the fact that it does occur as part of normal GC
activity explains the need for GC B cells to express FAS. It is
unclear at this point whether a specific cell type provides the
FASL required to prevent the development of GCr B cells. Our
data show that it is not an autocrine action of activated B cells
expressing FASL (Hahne et al., 1996). However, FASL could
instead derive from neighboring B cells, follicular dendritic cells
(Verbeke et al., 1999), Tfh/Tfr CD4+ cells (Rathmell et al., 1995),
or even CD8+ T cells (Afshar-Sterle et al., 2014). What feature
of GCr B cells makes them particularly susceptible to the signals
delivered through FAS is another question that requires further
investigation. Until more functional and phenotypic data have
been obtained, we propose that GCr B cells be defined as arare subpopulation of GC B cells that (1) accumulate late in the
GC response when FAS expression or function is impaired, (2)
do not require ongoing antigen binding to survive, and (3) show
a high propensity for PC differentiation including unusually large
numbers of IgE+ PCs.
Another context in which FAS has been identified to regulate
autoantibody production is the accumulation of extrafollicular
PCs that undergo chronic stimulation and GC-independent
SHM in response to autoantigens such as rheumatoid factor
(RF) (William et al., 2002). We determined that the accumulation
of SHM in the extrafollicular PCs derived from SWHEL.Fas
lpr/lpr
B cells does not occur via this mechanism because (1) the PC
population we observed did not express AID, (2) unlike the
anti-RF PCs (Herlands et al., 2008), the PC population we
observed did depend on ongoing T cell help, and (3) clear clonal
precursor-product relationships existed between the GC and PC
populations in our model.
An unexpected finding was that GCr B cells act as a source of
IgE-secreting PCs that emerge when responding B cells lack
functional FAS. The close clonal relationships between IgG1+
and IgE+ PCs in single recipient mice and evidence of multiple
IgE switching events indicate that most IgE+ PCs are generated
from IgG1+ GC B cells, potentially via a transient IgE+ GC B cell
intermediate (Erazo et al., 2007; Xiong et al., 2012; Yang et al.,
2012). Interestingly, human allergic and non-allergic IgE anti-
bodies often exhibit evidence of reduced antigenic selection
(Dahlke et al., 2006; Wang et al., 2014), consistent with IgE in
these cases being derived at least in part from GCr B cell clones
such as those described here.
The greatly elevated concentrations of serum IgE detected in a
major cohort of ALPS patients is consistent with the properties of
the GCr B cells that emerge when FAS is inactivated. The lack of
allergic disease among these patients also fits this scenario and
points to a link between IgE production and autoimmunity that is
independent of allergy. Further evidence for this phenomenon
comes from the recent finding that a majority of SLE patients
display IgE autoantibodies (Dema et al., 2014b). Similarly, inves-
tigations in a mouse model of SLE have demonstrated a role for
IgE in disease progression (Dema et al., 2014a) and IgE autoan-
tibodies have a clear pathogenic role in BP (Messingham et al.,
2014). Our findings therefore provide a mechanistic basis for
the link between IgE antibody production and autoimmune dis-
eases. We propose that the emergence of GCr B cells, through
mutation of FAS or potentially other immunoregulatory disrup-
tions, represents a common phenomenon in autoimmune dis-
ease that can not only drive the production of IgG autoantibodies
but support the parallel production of pro-inflammatory IgE that
might amplify disease. Further investigation of the signals that
drive GCr B cells might therefore reveal new strategies for man-
aging antibody-mediated autoimmune diseases.
EXPERIMENTAL PROCEDURES
Mice and Adoptive Transfers
SWHELmice (Phanet al., 2003)weremaintained on aCD45.1 congenic (Ptprc
a/a)
C57BL/6 background and mHEL4X transgenic mice (Chan et al., 2012) on a
C57BL/6background.All othermousestrainswereC57BL/6andare referenced
in Supplemental Experimental Procedures. For adoptive transfers, spleen
cells fromdonorSWHELmicecontaining 33 10
4HEL-bindingBcellswere trans-
ferred i.v. into wild-type or mHEL4X Tg recipient mice together with 2 3 108Immunity 42, 890–902, May 19, 2015 ª2015 Elsevier Inc. 899
HEL3X-SRBCs (prepared as previously described) (Paus et al., 2006).
Recipient mice were boosted with HEL3X-SRBCs (2 3 108 cells/recipient)
4 days after primary immunization. To abrogate GC B cell responses, 200 mg
of anti-CD40L mAb (MR-1, BioXcell) or isotype control (hamster IgG,
BioXcell) was administered intravenously on days 15, 17, and 19 after primary
immunization.
HEL Proteins
Purified wild-type hen egg lysozyme (HELWT) was purchased from Sigma-
Aldrich. Recombinant HEL3X and HEL4X proteins (Chan et al., 2012; Paus
et al., 2006) were grown as secreted proteins in yeast (Pichia pastoris) and
purified from culture supernatants as described (Paus et al., 2006).
Flow Cytometric Analysis
Splenocytes were prepared and stained for cell surface HEL3X or HEL4X bind-
ing as well as expression of other cell surface markers as described (Chan
et al., 2012). In addition, splenic basophils were identified with the following
mAbs: anti-FcεRI (MAR-1, eBioscience), anti-CD49b (DX5, BD Biosciences),
and anti-c-Kit (2B8, BD Biosciences). For flow cytometric analysis of fixed
and permeablized cells (Figure S2A), cells were first stained for surface
markers and surface IgE (including CD23-bound soluble IgE) blocked with un-
conjugated anti-IgE (R35-72) antibody (Yang et al., 2012). Thus, for fixed and
permeablized samples, IgG1 stains include surface and intracellular molecules
(total) whereas IgE stains are for intracellular (i.c.) IgE only. After surface
staining, cells were fixedwith 10% formalin (Sigma-Aldrich). Cell permeabiliza-
tion and subsequent staining steps were performed in 0.5% Saponin/0.1%
BSA/PBS. Intracellular staining was performed with 200 ng/ml of HELWT or
50 ng/ml of HEL3X. After staining for IgG1 (A85-1, BD Biosciences), samples
were blocked with 10% normal mouse serum (Jackson ImmunoResearch)
and bound HELWT/HEL3X was revealed with HyHEL9-AlexaFluor647 in 5%
normal mouse serum. Subsequent intracellular staining was performed with
anti-IgE FITC (R35-72, BD Biosciences) and Streptavidin (SA)-Pacific Blue
(Invitrogen). Data were acquired on either the FACS CantoII or LSR II SORP
(BD) and analyzed with FlowJo (TreeStar).
Single-Cell Sorting
To sort single cells for RNA extraction (Figure S2B), cell suspensions from
whole spleens were prepared and surface staining performed as detailed
earlier for surface flow cytometric analysis. For somatic hypermutation
(SHM) analysis (Figure S3B), cell samples were subjected to intracellular stain-
ing. Single-cell sorting was performed on the FACSAria, FACSAriaII, or Influx
(BD Biosciences).
Single-Cell qRT-PCR and Data Analysis
Acquisition and analysis of single-cell qRT-PCR data to determine mRNA
expression in sorted cells was carried out according to the methods estab-
lished by us (Suan et al., 2015) and described in detail in Supplemental Exper-
imental Procedures.
SHM Analysis
The variable region exon of the SWHEL Ig (HyHEL10) heavy chain gene was
amplified from sorted single cells by PCR and sequenced as described
(Paus et al., 2006).
ELISAs
IgE concentrations in sera were measured by direct ELISA and anti-HEL IgE
measured by capturing total serum IgE and detecting with biotinylated HEL.
These procedures are described fully in Supplemental Experimental Proce-
dures. Anti-HEL4X IgG1 was measured by direct ELISA with plate-bound
HEL4X mice as described (Chan et al., 2012).
ALPS Cohort Description and Human Serum IgE Measurements
The National Institute of Allergy and Infectious Diseases, National Institutes
of Health (NIAID, NIH) ALPS program has evaluated patients and family
members through mail-in samples and direct evaluation at the NIH Clinical
Center (NIH CC) since 1993. 415 individuals from 120 families with 95
unique FAS mutations were investigated (http://www.ncbi.nlm.nih.gov/
lovd/home.php?select_db=FAS). All participants underwent informed con-900 Immunity 42, 890–902, May 19, 2015 ª2015 Elsevier Inc.sent process and were enrolled on an IRB-approved NIAID, NIH research
protocol (Clinical trials.gov NCT: NCT00001350). Samples analyzed for
this study correspond to the 150 ALPS-FAS patients (78 probands and 72
affected relatives) and 63 healthy mutation-positive relatives whose natural
histories were recently reported (Price et al., 2014). Serum IgE measure-
ments were performed with IMMULITE 2000 analyzer (Siemens) with a
IMMULITE 2000 Total IgE kit for a solid-phase, chemiluminescent immuno-
metric assay.
Immunofluorescence Histology
Immunofluorescence histology analysis of splenic sections from recipient
mice was carried out as described previously (Chan et al., 2009) and outlined
in detail in Supplemental Experimental Procedures.
Recombinant HyHEL10 IgG1 Antibody Production and Binding
Analysis
Heavy chain mutants of HyHEL10 were expressed as soluble IgG1 molecules
in HEK293F cells from pcDNA3 vectors encoding mutant g1 heavy and wild-
type k light chains and purified via Protein G sepharose (AcroBiosystems).
Purified IgG1 samples were biotinylated at a 5:1 molar ratio via EZ-Link
NHS-PEG4-Biotinylation reagent (Thermo Scientific) and uncoupled bio-
tinylation reagent was removed with a ZebaSpin desalting column (Thermo
Scientific). Affinities of HyHEL10 variants were measured via the Blitz system
(PALL). SA biosensors were pre-blocked with 1% BSA/PBS for 1 hr. Sensors
were then incubated with dilute samples of biotinylated antibody and coupling
of antibody quantifiedwith the Blitz software. Coupled sensors were incubated
in PBS for 60 s to obtain a stable baseline and then incubated with various
dilutions (5 nM–5 mM) of purified, filtered HEL3X, HEL4X, or HELWT in PBS.
Association and dissociation rates were measured with the Blitz software
and global fits of the resulting data were used to determine the Kd, ka, and
kd of each variant for HEL
WT and HEL3X. Ka was taken as 1/Kd.
Statistical Analysis
A full description of statistical analyses used can be found in Supplemental
Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.immuni.2015.04.010.
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